Malignant neoplasm of gastrointestinal tract
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, the predictive value of HER2 overexpression depends on the tumor type, and results of breast cancer trials cannot a priori be extrapolated to digestive cancers.
|
31170116 |
2019 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations in several genes are reportedly involved in the progression of gastrointestinal cancer, including tumor protein 53 (<i>TP53</i>), APC regulator of WNT signaling pathway (<i>APC</i>), KRAS proto-oncogene GTPase (<i>KRAS</i>) and erb-b2 receptor tyrosine kinase 2 (<i>ERBB2</i>).
|
31452757 |
2019 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this project was to compare HER2 status in GI cancer brain metastases versus matched prior sites of disease in order to determine if HER2+ disease is more common intracranially.
|
30373904 |
2019 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consequently, HER2 targeting is established in breast and upper gastrointestinal tract cancer.
|
30621632 |
2019 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
|
30092682 |
2018 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer.
|
29344282 |
2018 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
The HER2/HER3 alteration in gastrointestinal cancers is quite interesting.
|
26619359 |
2016 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preclinical studies in HER2-amplified gastrointestinal cancer models have shown that cotargeting HER2 with a monoclonal antibody and a small molecule is superior to monotherapy with either inhibitor, but the underlying cooperative mechanisms remain unexplored.
|
26296355 |
2015 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, predictive biomarkers for gastrointestinal cancers include Her2 overexpression or amplification (gastroesophageal adenocarcinoma), c-Kit overexpression (gastrointestinal stromal tumors) and RAS wild-type (colorectal cancer).
|
25924988 |
2015 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among these, inhibitors of the epidermal growth factor receptor and HER2/neu pathways now play a major role in the management of gastrointestinal cancers in addition to other solid malignancies.
|
22229849 |
2012 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
Update on HER2 testing for breast and upper gastrointestinal tract cancers.
|
21657840 |
2011 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
CTD_human |
HER2 Testing in Gastric/Gastroesophageal Junction Adenocarcinomas: Unique Features of a Familiar Test.
|
21673877 |
2011 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells.
|
20116405 |
2010 |
Malignant neoplasm of gastrointestinal tract
|
0.400 |
Biomarker
|
disease |
BEFREE |
EGFR and HER2 protein expression were determined in a panel of 14 human upper gastrointestinal cancer cell lines and HER2 status was assessed by fluorescent in situ hybridization.
|
20179222 |
2010 |